Skip to main content
OpenTrials
Completed

NCT Number: NCT02650531

Norwegian COgnitive Impairment After STroke (NorCOAST) Study

A prospective observational multicenter study aiming to describe incidence, and identify predictors for development of poststroke dementia (PSD) and mild cognitive impairment (MCI) after stroke

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Norwegian University of Science and Technology

Trondheim, 7006, Norway

About this study

About 15000 Norwegians suffer a stroke every year and 2/3 will be more or less disabled. In addition to motor impairments and comorbidities, disability after stroke is often related to post stroke dementia (PSD) or mild neurocognitive disorder (NCD). However, these problems are hardly addressed in stroke or dementia research and frequently ignored in clinical practise. In the Nor-COAST study an interdisciplinary research group will collaborate to establish a research platform across all Norwegian Health Authorities. The overall aim of the study is to improve competence on PSD and NCD in order to improve individual health outcomes following a stroke. The specific objectives are to determine the incidence of PSD and NCD and the consequences on function and use of health care services and to enhance the early detection of PSD and NCD by identifying a set of risk factors, ranging from genetics to physical activity. The incidence and impact of PSD and NCD on function and use of health care services, medication and life-style changes are important when planning future health care services. Tools identifying patients at risk might improve diagnostic work up and together with knowledge on pathogenic aspects it will contribute to future treatment and prevention of PSD and NCD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Stroke diagnosis according to the WHO criteria

Exclusion criteria

  • Not scandinavian speaking

Treatment and study plan

Primary outcomes

  1. Score on the Montreal cognitive assessment (MOCA)

    Time frame: 18 months

    Performance based test

Secondary outcomes

  1. Score on the Montreal cognitive assessment (MOCA)

    Time frame: 3 months

    Performance based test

  2. Time spent in upright position

    Time frame: 3 months

    measured by bodyworn sensors

  3. Time spent in upright position

    Time frame: 18 months

    measured by bodyworn sensors

  4. Brain Imaging

    Time frame: 18 months

    MRI

  5. Score on Short Physical Performance Battery (sppb)

    Time frame: 3 months

    Performance based test for mobility and lower extremity function

  6. Score on Short Physical Performance Battery (sppb)

    Time frame: 18 months

    Physical function by performance based tests

  7. Selfreported habits concerning smoking, alcohol, diet and medication using standardised questionnaires

    Time frame: 3 months

  8. Selfreported habits concerning smoking, alcohol, diet and medication using standardised questionnaires

    Time frame: 18 months

Sponsors and collaborators

Lead sponsor

Norwegian University of Science and Technology

Other

Collaborators

  • Haukeland University Hospital
  • Ullevaal University Hospital
  • University Hospital of North Norway
  • Vestre Viken Hospital Trust

Registry information

Acronym: Nor-Coast

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Jan 8, 2016
Registry last updated
Feb 23, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.